NEW YORK (GenomeWeb News) – Horizon Discovery announced on its website today that it has inked a collaborative agreement with Janssen Pharmaceutica division Ortho Biotech Oncology Research & Development.

Cambridge, UK-based Horizon said that the deal covers the licensing of certain of its X-MAN cell lines including major cancer-causing genes and their matched normal genetic backgrounds. Horizon said that the cell lines could help the J&J unit to gather information related to selectivity and mode of action of drug candidates.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.